- Previous Close
9.040 - Open
9.090 - Bid 9.500 x --
- Ask 9.490 x --
- Day's Range
9.050 - 9.960 - 52 Week Range
6.030 - 21.350 - Volume
7,058,000 - Avg. Volume
3,141,251 - Market Cap (intraday)
9.176B - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.860 - Earnings Date Aug 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.27
Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China. The company offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; SkyWalker, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. It also offers spine surgical robots for spine surgery; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery. In addition, it manufactures parts of surgical robot devices; engages in assembly and distribution of surgical robot devices; research and development of system, as well as investment activities. Shanghai MicroPort MedBot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. The company operates as a subsidiary of Shanghai Latent Artificial Intelligence Co., Ltd.
www.medbotsurgical.comRecent News: 2252.HK
View MorePerformance Overview: 2252.HK
Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2252.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2252.HK
View MoreValuation Measures
Market Cap
9.24B
Enterprise Value
9.59B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
53.53
Price/Book (mrq)
30.83
Enterprise Value/Revenue
56.30
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.33%
Return on Equity (ttm)
-126.88%
Revenue (ttm)
156.23M
Net Income Avi to Common (ttm)
-750.32M
Diluted EPS (ttm)
-0.860
Balance Sheet and Cash Flow
Total Cash (mrq)
221.05M
Total Debt/Equity (mrq)
209.90%
Levered Free Cash Flow (ttm)
-242.37M